Type 2 Diabetes Clinical Trial
— DPPHoopsOfficial title:
Leveraging Recreational Basketball to Increase Participation in the National Diabetes Prevention Program (NDPP) Among Adults Aged 18-44 Years at Kaiser Permanente Georgia
Verified date | April 2024 |
Source | Kaiser Permanente |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the efficacy of adapting the National Diabetes Prevention Program (NDPP) to include recreational sports in effort to increase physical activity (PA) and promote lifestyle changes that can help reduce the risk of developing Type 2 Diabetes Mellitus. The hypothesis is that both the traditional NDPP and the NDPP+ Basketball will be considered feasible. The primary outcome is to assess whether the intervention (NDPP+BB) compared to the standard of care (NDPP only) will result in greater weight loss, lower A1c, and increased engagement in physical activity.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | November 30, 2024 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 44 Years |
Eligibility | Inclusion Criteria: - Aged 18-44 years - BMI >= 25 kg/m2 - Previous diagnosis of prediabetes as defined: - HbA1c 5.7 to 6.4% at baseline - Not engaged in high exercise levels (self-report of less than 300 minutes of exercise per week) - Not engaged in other lifestyle intervention program in past 2 years - Ability to read in English and provide informed consent - Ability to walk unassisted for 30 minutes - Ability to jump in place Exclusion Criteria: - Diabetes due to underlying conditions - Type 1 Diabetes - Type 2 Diabetes - End Stage Renal Disease (ESRD) - Myocardial Infarction within the last 12 months - Cancer treatment - Congestive Heart Disease - Not currently pregnant - Any history of seizures or uncontrolled neurologic or psychiatric condition that may interfere with the intervention plan |
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente Georgia, Center for Research and Evaluation | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Kaiser Permanente |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Weight Loss Efficacy | Compare percent of program participants achieving 5% or more weight loss between the DPP Standard of care group and the DPP+BB intervention group. | 12 months | |
Secondary | Blood pressure | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean systolic and diastolic blood pressure (mm Hg) | 12 months | |
Secondary | HbA1c | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean HbA1c (percent) | 12 month | |
Secondary | Aerobic Fitness | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean aerobic fitness (ml/kg/min) | 12 months | |
Secondary | Lipid profile | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean handgrip strenght (pounds) | 12 months | |
Secondary | Session attendance | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean number of program sessions attended | 12 months | |
Secondary | Physical activity | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean minutes per day of objectively measured sedentary, moderate and vigorous physical activity | 12 months | |
Secondary | Waist Circumference | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean waist circumference (cm) | 12 months | |
Secondary | % Fat | Compare changes between the DPP Standard of care group and the DPP+BB intervention group in mean % body fat derived from impedance measurements | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |